Facts & Figures

1.9 million
New Incidents of Colon Cancer*

*Source: GLOBOCAN 2020
50 million
Colonoscopies Performed
Worldwide*

*Numbers for the US, Canada, Germany, France, Italy, Spain, the UK, Japan, China, South Korea, Australia and India.
As of 2019
100
Diseases or Conditions Treated

At Olympus we have versatile medical devices
with the ability to treat approximately
100* diseases or conditions

*As of March 2022
TOP 4
Cancers Treated

Olympus provides products/solutions for lung, stomach, colon and prostate cancers - the top 4* highest incidence of cancers
*Top 4 highest incidence of caners excluding breast cancer, as of March 2022.
Source: GLOBOCAN 2020
31,557
Employees Worldwide*

39
Countries or Regions*

*As of March 2022
¥737.1bn
Total Medical
Revenue FY2022*

Medical Business occupies
the largest part of our revenue

*Figures are fiscal year revenues as of March 2022
70%
Global Market Share*

Olympus is the leader in
gastrointestinal endoscopic equipment

*As of Nov 2021
70%
Olympus R&D*
expenditures

are dedicated to the medical business.

*Research and development for fiscal year ending March 2022.
291
Awards

Since 1966, Olympus has been consistently
honored with national and international design
awards for its innovative product designs.*

*As of March 2022
17,000
Patents

across our product portfolio*

*As of March 2022
CO2“0”
Net zero CO2 emissions by 2030

We set as a target of achieving net zero CO2 emissions by 2030 from our site operations
TOP 100
Global Innovator

Since 2012 to 2020, and in 2022, Olympus has been
awarded as one of the top 100 most
innovative companies in the world.
https://clarivate.com/top-100-innovators/